Prestige Diagnostics U.K. Ltd - Period Ending 2019-03-31

Prestige Diagnostics U.K. Ltd - Period Ending 2019-03-31


Prestige Diagnostics U.K. Ltd NI610548 false 2018-04-01 2019-03-31 2019-03-31 The principal activity of the company is the selling and distribution of medical supplies Digita Accounts Production Advanced 6.24.8820.0 Software true NI610548 2018-04-01 2019-03-31 NI610548 2019-03-31 NI610548 bus:OrdinaryShareClass1 2019-03-31 NI610548 core:RetainedEarningsAccumulatedLosses 2019-03-31 NI610548 core:ShareCapital 2019-03-31 NI610548 core:CurrentFinancialInstruments 2019-03-31 NI610548 core:CurrentFinancialInstruments core:WithinOneYear 2019-03-31 NI610548 core:Non-currentFinancialInstruments 2019-03-31 NI610548 core:Non-currentFinancialInstruments core:AfterOneYear 2019-03-31 NI610548 core:FurnitureFittingsToolsEquipment 2019-03-31 NI610548 bus:SmallEntities 2018-04-01 2019-03-31 NI610548 bus:AuditExemptWithAccountantsReport 2018-04-01 2019-03-31 NI610548 bus:FullAccounts 2018-04-01 2019-03-31 NI610548 bus:SmallCompaniesRegimeForAccounts 2018-04-01 2019-03-31 NI610548 bus:RegisteredOffice 2018-04-01 2019-03-31 NI610548 bus:Director1 2018-04-01 2019-03-31 NI610548 bus:OrdinaryShareClass1 2018-04-01 2019-03-31 NI610548 bus:PrivateLimitedCompanyLtd 2018-04-01 2019-03-31 NI610548 core:FurnitureFittingsToolsEquipment 2018-04-01 2019-03-31 NI610548 countries:NorthernIreland 2018-04-01 2019-03-31 NI610548 2018-03-31 NI610548 core:FurnitureFittingsToolsEquipment 2018-03-31 NI610548 2017-04-01 2018-03-31 NI610548 2018-03-31 NI610548 bus:OrdinaryShareClass1 2018-03-31 NI610548 core:RetainedEarningsAccumulatedLosses 2018-03-31 NI610548 core:ShareCapital 2018-03-31 NI610548 core:CurrentFinancialInstruments 2018-03-31 NI610548 core:CurrentFinancialInstruments core:WithinOneYear 2018-03-31 NI610548 core:Non-currentFinancialInstruments 2018-03-31 NI610548 core:Non-currentFinancialInstruments core:AfterOneYear 2018-03-31 NI610548 core:FurnitureFittingsToolsEquipment 2018-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: NI610548

Prestige Diagnostics U.K. Ltd

Annual Report and Unaudited Financial Statements

for the Year Ended 31 March 2019

D T Carson & Co.
Chartered Accountants
51-53 Thomas Street
Ballymena
Co Antrim
BT43 6AZ

 

Prestige Diagnostics U.K. Ltd

Contents

Balance Sheet

1 to 2

Notes to the Financial Statements

3 to 7

 

Prestige Diagnostics U.K. Ltd

(Registration number: NI610548)
Balance Sheet as at 31 March 2019

Note

2019
£

2018
£

Fixed assets

 

Tangible assets

4

24,944

40,278

Current assets

 

Stocks

5

2,430

2,500

Debtors

6

112,578

48,171

Cash at bank and in hand

 

522

2,512

 

115,530

53,183

Creditors: Amounts falling due within one year

7

(121,777)

(62,726)

Net current liabilities

 

(6,247)

(9,543)

Total assets less current liabilities

 

18,697

30,735

Creditors: Amounts falling due after more than one year

7

(8,793)

(18,578)

Provisions for liabilities

(4,739)

(7,653)

Net assets

 

5,165

4,504

Capital and reserves

 

Called up share capital

8

10

10

Profit and loss account

5,155

4,494

Total equity

 

5,165

4,504

For the financial year ending 31 March 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

 

Prestige Diagnostics U.K. Ltd

(Registration number: NI610548)
Balance Sheet as at 31 March 2019

Approved and authorised by the director on 9 December 2019
 

.........................................

Alan J Rodgers
Director

 

Prestige Diagnostics U.K. Ltd

Notes to the Financial Statements for the Year Ended 31 March 2019

1

General information

The company is a private company limited by share capital, incorporated in Northern Ireland.

The address of its registered office is:
51-53 Thomas Street
Ballymena
Co Antrim
BT43 6AZ

The principal place of business is:
43 Ballymena Business Centre
Galgorm
Ballymena
Co Antrrim
BT42 1FL

These financial statements were authorised for issue by the director on 9 December 2019.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Prestige Diagnostics U.K. Ltd

Notes to the Financial Statements for the Year Ended 31 March 2019

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Furniture, fittings and equipment

20% straight line basis

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

 

Prestige Diagnostics U.K. Ltd

Notes to the Financial Statements for the Year Ended 31 March 2019

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease. Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the Balance Sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the Profit and Loss Account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2018 - 2).

 

Prestige Diagnostics U.K. Ltd

Notes to the Financial Statements for the Year Ended 31 March 2019

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 April 2018

78,987

78,987

At 31 March 2019

78,987

78,987

Depreciation

At 1 April 2018

38,709

38,709

Charge for the year

15,334

15,334

At 31 March 2019

54,043

54,043

Carrying amount

At 31 March 2019

24,944

24,944

At 31 March 2018

40,278

40,278

5

Stocks

2019
£

2018
£

Other inventories

2,430

2,500

6

Debtors

2019
£

2018
£

Trade debtors

3,620

20,335

Other debtors

108,958

27,836

112,578

48,171

 

Prestige Diagnostics U.K. Ltd

Notes to the Financial Statements for the Year Ended 31 March 2019

7

Creditors

Creditors: amounts falling due within one year

Note

2019
£

2018
£

Due within one year

 

Bank loans and overdrafts

9

10,262

10,262

Trade creditors

 

86,954

(478)

Taxation and social security

 

-

63

Accruals and deferred income

 

3,100

5,500

Other creditors

 

21,461

47,379

 

121,777

62,726

Creditors: amounts falling due after more than one year

Note

2019
£

2018
£

Due after one year

 

Loans and borrowings

9

8,793

18,578

8

Share capital

Allotted, called up and fully paid shares

 

2019

2018

 

No.

£

No.

£

Ordinary Shares of £1 each

10

10

10

10

         

9

Loans and borrowings

2019
£

2018
£

Non-current loans and borrowings

Finance lease liabilities

8,793

18,578

2019
£

2018
£

Current loans and borrowings

Finance lease liabilities

10,262

10,262